e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine (General)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia

M.C. Azevedo; E.D.R.P. Velloso; V. Buccheri; D.A.F. Chamone; P.E. Dorlhiac-Llacer · 2014 · Brazilian Journal of Medical and Biological Research

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 13

Abstract by M.C. Azevedo; E.D.R.P. Velloso; V. Buccheri; D.A.F. Chamone; P.E. Dorlhiac-Llacer, Brazilian Journal of Medical and Biological Research (2014) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1590/1414-431x20144059